Anuh Pharma Ltd

Anuh Pharma has faced notable volatility, hitting a new 52-week low of Rs. 161 amid a downward trend. The stock has underperformed its sector and recorded a significant decline over the past year, contrasting with the overall market's gains. It remains below key moving averages, signaling ongoing challenges.

Anuh Pharma has faced notable volatility, reaching a new 52-week low of Rs. 162.7 and underperforming its sector. The stock has declined consecutively over two days, with an annual performance drop of 18.80%, contrasting with the Sensex's gain of 4.25%, indicating significant challenges in the market.

Anuh Pharma has reached a new 52-week low, reflecting a significant intraday decline amid a broader sector downturn. Over the past year, the company's stock has dropped notably, contrasting with the overall market's gains. Its trading levels remain below key moving averages, indicating ongoing challenges in the pharmaceutical sector.

Anuh Pharma, a microcap in the Pharmaceuticals & Drugs sector, is nearing a 52-week low, having declined 13.23% over the past three days. Despite slightly outperforming its sector today, the stock remains below its moving averages and has seen a 13.02% drop over the past year, contrasting with the Sensex's gains.

Anuh Pharma has reached a new 52-week low, continuing a downward trend with a notable decline over the past two days. The stock is trading below multiple moving averages, indicating a bearish outlook. Despite recent challenges, it has outperformed the Sensex over the past year.

Anuh Pharma has announced its financial results for the quarter ending February 2025, revealing a significant shift in its performance metrics. The company's score has seen a notable adjustment, indicating changes in its financial health that may be of interest to stakeholders as they assess its operational strategies.

Anuh Pharma has undergone a revision in its stock evaluation by MarketsMOJO, reflecting recent challenges such as flat results and a decline in operating cash flow. Despite a strong return on equity and attractive valuation metrics, the stock's sentiment has shifted to a mildly bearish range. Anuh Pharma has been added to MarketsMOJO's list, underscoring its long-term market performance.

Anuh Pharma has recently seen a revision in its score by MarketsMOJO, reflecting a shift in its market evaluation. The company, known for its strong financial metrics, including a low debt-to-equity ratio and a solid return on equity, has been added to MarketsMOJO's list. Despite a flat performance in recent financial results, Anuh Pharma's overall market position remains stable, supported by positive technical indicators and favorable growth prospects.

Anuh Pharma has recently undergone a revision in its score, reflecting its strong performance in the pharmaceuticals sector. The stock has been added to MarketsMOJO's list, showcasing its ability to outperform both its sector and the broader market. Despite this positive momentum, the stock continues to face a cautious outlook.

Anuh Pharma has recently experienced a revision in its score by MarketsMOJO, reflecting a shift in market sentiment. Despite facing challenges, including flat quarterly results and bearish technical indicators, the company maintains a strong return on equity and has outperformed the BSE 500 index over the past year. In a recent evaluation, Anuh Pharma's stock was added to MarketsMOJO's list, indicating ongoing interest in its potential despite the current market conditions. The company's stable financial structure, highlighted by a low debt-to-equity ratio, further supports its position in the pharmaceuticals sector.

Anuh Pharma has undergone a revision in its score by MarketsMOJO, reflecting a shift in its evaluation amid mixed financial indicators. The company maintains a solid financial structure with a low Debt to Equity ratio and has shown notable returns over the past year, despite recent flat results. In a recent analysis, Anuh Pharma's technical trend appears sideways, indicating a lack of clear price momentum. However, the stock has experienced a slight improvement from a previously bearish trend. The company's return on equity remains attractive, and it has been added to MarketsMOJO's list, highlighting its potential in the pharmaceuticals sector.

Anuh Pharma has experienced a revision in its score by MarketsMOJO, reflecting recent challenges in its financial performance. The stock's operating cash flow has notably declined, and technical indicators suggest a bearish trend. Despite a strong return on equity, the absence of mutual fund investment raises concerns about its market outlook. Anuh Pharma, a small-cap player in the pharmaceuticals sector, has been added to MarketsMOJO's list following a downgrade in its evaluation. The company's recent flat results and declining cash flow have prompted this adjustment, even as it maintains a low debt-to-equity ratio. While it has shown impressive returns over the past year, the lack of mutual fund interest may signal underlying valuation concerns.

Anuh Pharma has recently undergone a revision in its score, now receiving a 'Hold' rating from MarketsMOJO. The adjustment reflects the company's stable financial position, characterized by a low Debt to Equity ratio and attractive valuation metrics, despite a flat performance in recent results. In the latest analysis, Anuh Pharma's stock has demonstrated a sideways trend with improved technical indicators, achieving a modest return since early December. The company boasts a strong return on equity and has outperformed broader market indices over various time frames. However, the lack of significant mutual fund investment may indicate cautious sentiment among institutional investors. As the company navigates its financial landscape, investors are advised to monitor upcoming results and valuation shifts closely.

Anuh Pharma, a microcap pharmaceutical company, reported a flat performance for the quarter ending September 2024 with a score of -1. However, there has been an improvement from the previous quarter. The company's Dividend per Share has consistently grown over the past five years, but its Operating Cash Flow and Dividend Payout Ratio have declined. Investors should carefully evaluate these factors before investing.

On October 8th, 2024, Anuh Pharma's stock price increased by 7.37%, in line with the pharmaceutical and drugs industry. The stock had been declining for five days, but this recent rise may indicate a trend reversal. However, it is currently trading below its moving averages and has underperformed the market in the past month.

Anuh Pharma, a microcap pharmaceutical company, has been downgraded to a 'Sell' by MarketsMOJO due to negative results and a decrease in profits and operating cash flow. Despite a low debt to equity ratio and attractive valuation, the lack of interest from domestic mutual funds and a sideways technical trend may be cause for concern.

On August 12, 2024, Anuh Pharma ., a smallcap pharmaceutical company, saw a -8.16% decline in its stock price and has been given a 'Hold' call by MarketsMOJO. The stock underperformed the sector by -8.75% and opened with a significant loss of -12.26%. It has a mixed trend and has recently underperformed the overall market.

Anuh Pharma, a smallcap pharmaceutical company, reported a negative performance in the quarter ending June 2024, with a score of -11. However, the company has consistently shown growth in its dividend per share over the last five years. On the other hand, there are concerns regarding the decline in profit before and after tax, net sales, and operating cash flow. Investors are advised to hold their stock and monitor the company's performance.

Anuh Pharma, a smallcap pharmaceutical company, has been upgraded to a 'Buy' by MarketsMOJO on August 8, 2024. This is due to its low Debt to Equity ratio, consistent positive results, and bullish technical indicators. The stock is also attractively valued and has shown strong growth potential. However, the lack of confidence from domestic mutual funds may pose a risk for investors.